A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation.
Microglia are brain macrophages and, as such, key immune-competent cells that can respond to environmental changes. Understanding the mechanisms of microglia-specific responses during pathologies is hence vital for reducing disease burden. The definition of microglial functions has so far been hampered by the lack of genetic in vivo approaches that allow discrimination of microglia from closely related peripheral macrophage populations in the body. Here we introduce a mouse experimental system that specifically targets microglia to examine the role of a mitogen-associated protein kinase kinase kinase (MAP3K), transforming growth factor (TGF)-β-activated kinase 1 (TAK1), during autoimmune inflammation. Conditional depletion of TAK1 in microglia only, not in neuroectodermal cells, suppressed disease, significantly reduced CNS inflammation and diminished axonal and myelin damage by cell-autonomous inhibition of the NF-κB, JNK and ERK1/2 pathways. Thus, we found TAK1 to be pivotal in CNS autoimmunity, and we present a tool for future investigations of microglial function in the CNS.
1] Institute of Neuropathology, University of Freiburg, Freiburg, Germany. [2].
Tobias
0000000197549144
T
Goldmann
Peter
P
Wieghofer
Philippe F
PF
Müller
Yochai
Y
Wolf
Diana
D
Varol
Simon
S
Yona
Stefanie M
SM
Brendecke
Katrin
K
Kierdorf
Ori
O
Staszewski
Moumita
M
Datta
Tom
T
Luedde
Mathias
M
Heikenwalder
Steffen
S
Jung
Marco
M
Prinz
D000818:Animals; D000831:Animals, Newborn; D001253:Astrocytes / Q000187:drug effects / Q000502:physiology; D001921:Brain / Q000378:metabolism / Q000473:pathology*; D039521:CD11c Antigen / Q000235:genetics; D000073883:CX3C Chemokine Receptor 1; D002478:Cells, Cultured; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000139:chemically induced / Q000473:pathology*; D004965:Estrogen Antagonists / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects / Q000276:immunology*; D018390:Gene Targeting; D008164:Luminescent Proteins / Q000235:genetics; D008198:Lymph Nodes / Q000473:pathology; D020930:MAP Kinase Kinase Kinases / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D017628:Microglia / Q000187:drug effects / Q000502:physiology*; D009419:Nerve Tissue Proteins / Q000378:metabolism; D022661:RNA, Untranslated / Q000235:genetics; D019707:Receptors, Chemokine / Q000235:genetics; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D013629:Tamoxifen / Q000494:pharmacology; D000099151:MAP Kinase Kinase Kinase 7
D039521:CD11c Antigen; D000073883:CX3C Chemokine Receptor 1; D004965:Estrogen Antagonists; D008164:Luminescent Proteins; D020930:MAP Kinase Kinase Kinases; D009419:Nerve Tissue Proteins; D022661:RNA, Untranslated; D019707:Receptors, Chemokine; D013629:Tamoxifen; D000099151:MAP Kinase Kinase Kinase 7; C471885:Cx3cr1 protein, mouse; C110853:Gt(ROSA)26Sor non-coding RNA, mouse